Boundless Bio, Inc. (BOLD)
(Delayed Data from NSDQ)
$1.18 USD
0.00 (0.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.17 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BOLD 1.18 0.00(0.00%)
Will BOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BOLD
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
New Strong Sell Stocks for May 1st
BOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
January Effect Builds Up Momentum: 5 Small-Cap Stocks to Buy
Boundless Bio, Inc. (BOLD) Loses -19.52% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Down -31.59% in 4 Weeks, Here's Why You Should You Buy the Dip in Boundless Bio, Inc. (BOLD)
Other News for BOLD
Boundless Bio GAAP EPS of -$0.70
Boundless Bio (BOLD) Advances Cancer Therapies with Targeted Focus
Boundless Bio reports Q2 EPS (70c), consensus (65c)
Goldman Sachs Initiates Coverage on Boundless Bio (BOLD) with High Risk Note | BOLD Stock News